Xerostomia (Dry Mouth) Treatment Market

Market Study on Xerostomia (Dry Mouth) Treatment: High Demand to Be Witnessed for Oral Sprays

Xerostomia Treatment Market Segmented By Oral Sprays, Oral Solutions, Oral Liquids, Gels, Powders Product for Pediatrics, Adults

Industry: Healthcare

Published Date: March-2022

Format: PPT*, PDF, EXCEL

Delivery Timelines: Contact Sales

Number of Pages: 344

Report ID: PMRREP17236

Report Price

$ 4900*

Buy Now

Xerostomia (Dry Mouth) Treatment Market Outlook (2022-2032)

With a valuation of US$ 952.7 Mn in 2021, the global xerostomia (dry mouth) treatment market is set to exhibit growth at a CAGR of 6.1% to reach US$ 1.81 Bn by 2032.

Attribute Key Insights

Xerostomia Treatment Market Size (2021)

US$ 952.7 Mn

Estimated Market Value (2022)

US$ 1 Bn

Predicted Market Value (2032)

US$ 1.81 Bn

Global Market Growth Rate (2022-2032)

6.1% CAGR

Market Share of Top 5 Countries

51.7%

According to detailed industry analysis by Persistence Market Research, the oral spray segment held a market value of US$ 301.8 Mn in 2021, accounting for nearly 31% share of the global market for xerostomia treatment by product.

Dry mouth treatment accounted for a revenue share of 2% in the global oral care market, which was valued at US$ 47.2 Bn in 2021.

Xerostomia Treatment Demand Analysis from 2017 to 2021 Vs Market Outlook for 2022 to 2032

The global dry mouth treatment market expanded at a CAGR of 4.9% over the last five years (2017-2021).

Growing adoption of radiotherapy and chemotherapy in cancer treatment together with increasing use of prescribed medications are some of the major factors anticipated to drive xerostomia treatment market growth. Chemotherapy and radiation harm the salivary glands and lead to dry mouth. Chemotherapy is one of the most common practices for the treatment of cancer provided by medical practitioners and oncologists.

As per CDC (Centres for Disease Control & Prevention), every year, approximately 650,000 cancer patients undergo chemotherapy in an outpatient oncology facility.

Other factors boosting market growth are rising geriatric population base, cost-effectiveness, ease of availability of medicines, growing usage of prescription medicines, and rising prevalence of diseases such as diabetes, Alzheimer’s disease, Sjogren’s syndrome, and HIV, among others.

Major dry mouth treatment product manufacturers are keen to expand their market presence through key products as well as solutions for end users. For instance, many leading manufacturers nowadays also provide customized solutions based on various end-user requirements.

Market players are also striving to provide a total solution concept to customers, especially to end users, which, in turn, is supporting the growth of the xerostomia treatment industry.

  • For instance, in April 2021, Parnell Pharmaceuticals, Inc. introduced the Mouth Kote-MD mouth spray based on MycoDelens, a patented compound developed and licensed by New Mexico Tech University.

The global xerostomia treatment market is expected to expand at a CAGR of 6.1% over the forecast period and record sales worth US$ 1.81 Bn by the end of 2032.

xerostomia-dry-mouth-treatment-market

How Can Xerostomia Treatment Devices Manufacturers Progress in This Space?

“Increasing Usage of Medications Surging Dry Mouth Incidence”

The coming years are set to offer lucrative opportunities for manufacturers of xerostomia treatment devices around the world.

Growing incidence of Sjogren’s syndrome and increasing consumption of medications are major factors expected to create lucrative opportunities for market players. As per the National Institute of Dental and Craniofacial Research, over 400 medicines can lead to xerostomia.

“Rising Awareness Regarding Xerostomia Treatment Drugs”

Dentists and physicians are concentrating on recognizing patients who are susceptible to developing irreversible and serious oral issues so that they can provide information regarding the management and relief from symptoms, thus enhancing patients' quality of life. Hence, rising awareness amongst healthcare practitioners regarding diagnosis has generated significant opportunities in the market.

“Growing Drug Pipeline for Dry Mouth Treatment”

Rising interest of the pharmaceutical industry in the development of products in various forms such as gels, toothpaste, powders, liquids, and sprays will further expand the product pipeline. A strong product pipeline with increasing research & development activities will create lucrative opportunities for oral health product manufacturers.

What May Restrain Demand for Dry Mouth Treatment?

“Low Public Awareness and Limited Xerostomia Treatment Options”

Lack of awareness about xerostomia disease and availability of limited treatment options are key factors restraining demand growth for dry mouth treatment.

People are unaware of the oral complications of a few diseases such as HIV, cancer, and diabetes. They are also less aware of the severe consequences caused by xerostomia. One of the reasons is that patients never care to look for other treatments for dry mouth due to the availability of natural and home remedies. For example, individuals in India generally give preference to natural remedies.

As per a study conducted by the Department of Oral Medicine of Indonesia, approximately 20% of people were aware of the disease condition and 44% were moderately aware. Thus, lack of awareness regarding xerostomia disease and available treatment options is hampering market expansion.

Availability of alternative treatment options such as acupuncture or use of essential oils such as lavender oil, eucalyptus oil, etc., for dry mouth treatment, is further expected to limit market growth.

Country-Wise Insights

How is the U.S. Xerostomia Treatment Market Faring?

The U.S. is estimated to account for around 84.4% of the North America xerostomia treatment market in 2022, owing to better healthcare infrastructure and facilities, easy availability of treatment options, favorable reimbursement policies, and increasing awareness initiatives in the region.

Additionally, growing prevalence of xerostomia and other dry mouth-related diseases such as Sjogren’s syndrome, diabetes, Parkinson’s disease, and HIV, in the U.S., is boosting market growth.

  • For instance, the American College of Rheumatology reported that around 3.1 million people suffered from Sjogren's disorder in the U.S. in 2019.

What Makes Germany an Important Market for Xerostomia Treatment in Europe?

Germany is estimated to account for 23.1% of the Europe xerostomia treatment market in 2022.

With a constantly growing aging population, oral problems such as dry mouth are becoming more common. Moreover, medical professionals, healthcare providers, and dentists are constantly attempting to educate customers regarding the effects of xerostomia and other oral issues.

In addition, growing research activities, increasing product pipeline, and presence of major players are creating many opportunities for xerostomia treatment product manufacturers in Germany.

What Outlook Does India Provide for Dry Mouth Treatment Product Suppliers?

Demand for xerostomia treatment in India is expected to rise at around 6.5% CAGR over the forecast period, owing to growth in government initiatives for increasing awareness and rising prevalence of chronic diseases that lead to dry mouth conditions.

In emerging nations such as India, there is adoption of both, industrial and health policies for boosting domestic manufacturing of cancer drugs, which is resulting in lower therapy expenses. Lower therapy costs together with growing awareness regarding cancer are resulting in higher adoption of radiotherapy and chemotherapy, thus leading to the growth of the market in India.

Category-Wise Insights

Why are Oral Sprays Popular for Xerostomia Treatment?

By product, oral sprays for xerostomia treatment are anticipated to hold the highest market share of 32% in 2022, expanding at the rate of nearly 6.9% CAGR during the forecast period, owing to their efficiency, low cost, and increased rate of adoption amongst customers.

Oral spray solutions are widely used to manage dry mouth conditions. Healthcare providers are proactively recommending products to minimize the side effects of medications and thereby increase the quality of life.

Additionally, oral spray products are easily accessible to people as pharmacists or retailers keep these medicines in high amounts as they do not require a doctor’s prescription.

Why Do Adults Account for Highest Market Share?

By age group, the adult segment will lead the market and is projected to account for 90.4% market revenue share in 2022.

Dry mouth, or xerostomia, is common amongst adults, especially geriatric people, due to reduced salivary gland function. The primary causes of dry mouth in the adult population are due to the use of medications and radiation treatment to the neck and head region with increasing number of chronic disorders.

Hence, the growing adult population is expected to lead demand for xerostomia treatment by age group.

Will Mail Order Pharmacies Drive Sales of Xerostomia Treatment Product Manufacturers?

By distribution channel, mail order pharmacies are anticipated to hold the highest share of 26.3% in 2022, expanding at a rapid rate of 6.7% CAGR during the forecast period.

For the treatment of xerostomia, the most common are OTC products, which are easily available in pharmacies and online platforms. However, non-adherence to medication is a major problem that leads to poor outcomes. However, several studies have shown that there is better medication adherence with the use of mail order pharmacy deliveries.

In addition, several benefits offered by mail order pharmacies such as home delivery, health plan discounts, special customer services, and easy refill of medicines are expected to lead to high growth of the segment over the forecast period.

Competition Landscape

Leading xerostomia treatment product suppliers are adopting collaboration and joint venture strategies as part of their efforts to strengthen their market presence. Key players in the xerostomia (dry mouth) treatment industry have been constantly chasing approval authorities such as FDA or DCGA in order to launch new product variants that will help them increase their market presence.

For Instance:

  • In November 2020, GlaxoSmithKline Consumer Healthcare launched the global oral care and denture care brand – Polident - in India. With this introduction, GSK India has managed to enter the specialized denture care category.
  • In June 2021, ADVANZ PHARMA entered into an agreement in Europe, Russia, Australia and the Middle East to acquire rights to Eisai’s Zonegran.
  • In January 2022, ICPA Health Products Ltd. launched a mouthwash - CHLORHEXIDINE GARGLE.

Xerostomia Treatment Industry Report Scope

Attribute Details

Forecast Period

2022-2032

Historical Data Available for

2017-2021

Market Analysis

US$ Million for Value

Key Countries Covered

  • U.S.
  • Canada
  • Brazil
  • Mexico
  • Argentina
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • BENELUX
  • Russia
  • China
  • Japan
  • South Korea
  • India
  • Thailand
  • Malaysia
  • Indonesia
  • Australia
  • New Zealand
  • GCC Countries
  • Turkey
  • South Africa

Key Market Segments Covered

  • Product
  • Age Group
  • Distribution Channel
  • Region

Key Companies Profiled

  • GlaxoSmithKline Plc
  • Daiichi Pharmaceutical Co., Ltd.
  • Bausch Health Companies Inc. (OraPharma)
  • ADVANZ PHARMA Corp. Limited
  • CCMed Ltd.
  • Elevate Oral Care, LLC
  • Orahealth Corporation
  • Forward Science
  • Parnell Pharmaceuticals, Inc.
  • Cyclacel Pharmaceuticals, Inc.
  • Midatech Pharma Plc
  • The 3M Company
  • Mission Pharmacal
  • Chattem, Inc. (Sanofi)
  • Colgate-Palmolive Company
  • EUSA Pharma, Inc.
  • Others

Report Coverage

  • Market Forecast
  • Competition Intelligence
  • DROT Analysis
  • Market Dynamics and Challenges
  • Strategic Growth Initiatives

Customization & Pricing

Available upon Request

Key Segments Covered in Xerostomia Treatment Industry Survey

Xerostomia Treatment Market by Product:

  • Oral Sprays
  • Oral Solutions
  • Oral Liquids
  • Gels
  • Powders

Xerostomia Treatment Market by Age Group:

  • Paediatrics
  • Adults
    • Early Adults (18-34 Years)
    • Early Middle Age (35 – 44 Years)
    • Late Middle Age (45 – 64 Years)
    • Late Adulthood (Above 65+Years)

Xerostomia Treatment Market by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Mail Order Pharmacies
  • Hypermarkets and Supermarkets

Xerostomia Treatment Market by Region:

  • North America Xerostomia Treatment Market
  • Latin America Xerostomia Treatment Market
  • Europe Xerostomia Treatment Market
  • South Asia Xerostomia Treatment Market
  • East Asia Xerostomia Treatment Market
  • Oceania Xerostomia Treatment Market
  • Middle East & Africa Xerostomia Treatment Market

To know more about delivery timeline for this report Contact Sales

Companies Covered in This Report

  • GlaxoSmithKline Plc
  • Daiichi Pharmaceutical Co., Ltd.
  • Bausch Health Companies Inc. (OraPharma)
  • ADVANZ PHARMA Corp. Limited
  • CCMed Ltd.
  • Elevate Oral Care, LLC
  • Orahealth Corporation
  • Forward Science
  • Parnell Pharmaceuticals, Inc
  • Cyclacel Pharmaceuticals, Inc.
  • Midatech Pharma Plc.
  • Perrigo Company Plc.
  • Entod International
  • Laboratories Kin, SA
  • ICPA HEALTH PRODUCTS Ltd
  • Biocosmetic Laboratories
  • The 3M Company
  • Mission Pharmacal Company
  • Chattem, Inc. (Sanofi)
  • Cipla Ltd.
  • Fresenius Kabi
  • Colgate-Palmolive Company
  • EUSA Pharma

Frequently Asked Questions

The global xerostomia treatment market was valued at the US$ 952.7 Mn in 2021, and is expected to grow 1.8X by 2032.

The market for xerostomia treatment expanded at 4.9% CAGR during 2017 through 2021.

Oral sprays held 31.7% of the total market share in 2021.

The U.S., China, Germany, France, and Canada hold more than 50% of the global market share.

The North America xerostomia treatment market is led by the U.S., which is anticipated to account for 84.4% of the regional market in 2022.

The Europe dry mouth treatment market is expected to record a CAGR of 6.4% over the forecast period.

The U.S. and U.K. are major producers of dry mouth treatment solutions.

China held a share of 54.7% in the East Asia xerostomia treatment market in 2021, and India accounted for a share of 38.3% in the South Asia market.

Thank you for taking time to visit our website, click like if you found the information on this page useful?

This site uses cookies, including third-party cookies, that help us to provide and improve our services.
Google translate